Physician profile
Siby Thomas
NPI 1497140867
$3,196.19
in general payments reported to CMS, 2019-2025
24 companies · $867 in 2025
The $867 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $688 · 2022: $541 · 2023: $471 · 2024: $629 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $720.29 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $483.54 | 2021-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $470.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.41 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $178.27 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $136.81 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $109.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $105.03 | 2021-2023 | Steglujan, Steglatro, Belsomra |
| Pfizer INC. | $82.83 | 2021-2024 | |
| Amarin Pharma, INC. | $82.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.64 | 2021-2025 | |
| Abbvie INC. | $74.86 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $69.23 | 2024 | Voquezna |
| Astellas Pharma US INC | $60.04 | 2022-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $54.80 | 2023-2025 | Zoryve, Livalo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.44 | 2022-2023 | |
| Abbott Laboratories | $49.36 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $43.25 | 2022-2023 | |
| Viatris Specialty LLC | $26.35 | 2025 | Yupelri |
| Phadia US INC. | $22.15 | 2025 | Immunocap |
| Dexcom, INC. | $19.79 | 2022 | |
| Evoke Pharma, INC. | $19.01 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siby Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.